May 25, 2017 08:13 AM EDT
Pharma

Mys­tery biotech Em­maus grabs ground­break­ing FDA pan­el back­ing for sick­le cell drug — af­ter qui­et­ly scrap­ping $225M deal

John Carroll

Editor & Founder

A lit­tle-known biotech out of Tor­rance, CA is one big step clos­er to win­ning the first new drug ap­proval for sick­le cell dis­ease in close …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A look at biotech's year of the megaround

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

A service from the Financial Times